These findings unveil a TFE3‐driven transcriptional circuit that sustains therapeutic resistance via metabolic symbiosis, positioning PCYT1A inhibition as a strategy to disrupt CAF‐tumor crosstalk in prostate cancer. This evidence concerns the gene PCYT1A and Familial prostate cancer.